Medinno logo — Expert of Cell Therapeutics for Brain Diseases

Medinno

Expert of Cell Therapeutics for Brain Diseases

Founded 2018 Korea South Korea South 7 employees Series C Total: $8.17M Biotechnology, Health Care +1

General Information

Company Name Medinno
Founded Year 2018
Location Korea South Korea South
Employees 7
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Medinno. To contact Medinno, visit medinno.kr.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Medinno

Medinno Inc. is a biotechnology and healthcare company based in Korea South, founded in 2018. With the slogan "Expert of Cell Therapeutics for Brain Diseases," Medinno has been dedicated to developing cell therapeutics for brain diseases for over 15 years. Their commitment to providing hope to countless patients and families suffering from brain diseases is commendable. The company recently secured a significant $8.17M Series C investment on 16 October 2023. The investors in this latest round include CJ Investment, Kingo Investment Partners, MINT Venture Partners, BNH Investment, and CKD Venture Capital Corporation. Their focus on addressing critical medical needs and the support from prominent investors positions Medinno as a key player in the biotechnology and healthcare industries.

Taxonomy: Cell therapy, Gene therapy, Neural stem cell, Mesenchymal stem cell, Hypoxic ischemic encephalopathy, Intraventricular hemorrhage, Spinal cord injury, Stroke, Brain tumor

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $8.17M 5
CJ Investment, Kingo Investment Partners +3
16 Oct 2023
Venture Round Undisclosed 1
Company K Partners
01 Jan 2019

Medinno Alternatives & Competitors

View All Alternatives
Medinno vs

Oligogen, Inc. is a biotech startup developing stem cell therapies for central nervous system diseas...

Venture round
1 employees
Biotechnology, Care Economy
Medinno vs

Advancing stem cell technology to treat central nervous system diseases and deliver hope for incurab...

Post-IPO Equity
3 employees
Biotechnology, Health Care
Medinno vs

A Gene Therapy Company Leading Neural Regeneration and Repair

Seed
5 employees
Biotechnology, Health Care

FAQ About Medinno

Expert of Cell Therapeutics for Brain Diseases
Medinno was founded in 2018.
Medinno is headquartered in Korea South.
Medinno operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Cell therapy, Gene therapy, Neural stem cell and Mesenchymal stem cell.
Medinno has approximately 7 employees.
Medinno has completed 2 funding rounds, raising a total of $8.17M. The latest funding stage is Series C.
Top alternatives and competitors to Medinno include Oligogen, Inc., Neuralstem, Inc., NeuExcell Therapeutics, Stemedica Cell Technologies, Inc, Hopstem Biotechnology Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Medinno and Oligogen, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Medinno, https://bouncewatch.com/company/medinno, updated 14 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes